RxDoctor Payments Data
★ My doctorsLook up a doctor →

Hiralal Maheshwari

Endocrinology, Diabetes & Metabolism · McHenry, ILNPI 1740238757

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $62,633 of the $86,036 with a category attached, or 72.8%. 45 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 43.1% of the total. Reporting peaked in 2022 at $23,135 and has fallen 81.1% since, to $4,368 in 2023. Among endocrinology, diabetes & metabolism clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$86,036in general payments, 2019–2025

Across 1,028 payments — averaging $83.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi-aventis U.S. LLC$37K
  • Bayer$17K
  • AstraZeneca$15K
  • Johnson & Johnson$2K
  • Dexcom, Inc.$2K
  • Lilly USA, LLC$2K
  • plus $10K from 39 others
$558,159in research payments, 2019–2025

Across 105 payments — averaging $5315.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$265K
  • Sanofi US Services Inc.$230K
  • Novartis$39K
  • Lexicon Pharmaceuticals, Inc.$15K
  • AstraZeneca$8K
  • Eli Lilly$2K

What the payments were for

  • Speaking & faculty fees$62,63373%
  • Travel & lodging$2,7003%
  • Food & beverage$20,65724%
  • Education$460%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi-aventis U.S. LLC115$37,070
Bayer36$17,467
AstraZeneca(2 entities)76$14,700
Johnson & Johnson10$2,483
Dexcom, Inc.74$2,003
Lilly USA, LLC122$1,840
Boehringer Ingelheim92$1,487
Abbott87$1,137
Corcept Therapeutics50$1,073
Mannkind Corporation63$863
AbbVie45$738
Amgen(2 entities)35$666
Tandem Diabetes Care, Inc.13$643
Merck39$625
Amneal Pharmaceuticals LLC27$518
IBSA Pharma Inc.23$372
Radius Health, Inc.21$341
Antares Pharma, Inc.16$327
BD6$194
Medtronic(2 entities)5$164
Eisai Inc.12$137
Novo Nordisk6$130
Xeris Pharmaceuticals, Inc.6$113
Novartis1$108
Shire North American Group Inc4$97
Recordati_rare_diseases_inc.5$93
Clarus Therapeutics Inc.7$91
Vivus LLC7$90
Halozyme Inc3$59
Insulet Corporation2$44
Sun Pharmaceutical Industries Inc.2$39
Azurity Pharmaceuticals, Inc.2$39
Amarin Pharma, Inc.2$36
Kyowa Kirin, Inc.2$35
Currax Pharmaceuticals LLC2$32
Ultragenyx Pharmaceutical Inc.1$24
Embecta Corp.1$23
Amphastar Pharmaceuticals, Inc.1$19
Zealand Pharma US, Inc.1$19
Esperion Therapeutics, Inc.1$19
Lexicon Pharmaceuticals, Inc.1$19
Companion Medical, Inc.1$17
Pfizer1$16
Aytu Biopharma, Inc.1$16
Lifescan, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$86,036 in reported general payments places this provider in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

See all endocrinology, diabetes & metabolism providers in Illinois →

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide25$35,253
TrulicityDulaglutide18$29,754
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog13$27,041
Soliqua 100-33Insulin Glargine/Lixisenatide23$27,031
JardianceEmpagliflozin18$25,521
FarxigaDapagliflozin Propanediol16$21,580
Tresiba Flextouch U-200Insulin Degludec11$21,035
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$20,056
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$15,449
JanuviaSitagliptin Phosphate14$15,305
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$10,882
Novolog FlexpenInsulin Aspart22$8,123
Humalog Kwikpen U-100Insulin Lispro18$3,631
Nano 2nd Gen Pen NeedlePen Needle, Diabetic34$2,938
Ultra-Fine Short Pen NeedlePen Needle, Diabetic17$1,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$130$35,25325 claims
Lilly USA, LLCTrulicity$1,840$29,75418 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$37,070$27,03123 claims
Boehringer IngelheimJardiance$1,487$25,52118 claims
AstraZenecaFarxiga$14,700$21,58016 claims
MerckJanuvia$625$15,30514 claims
AbbVieSynthroid$738$1,24012 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$518$1,06798 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.

Other endocrinology, diabetes & metabolism in McHenry

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →